Nano-sized cytochrome P450 3A4 inhibitors to block hepatic metabolism of docetaxel

Most drugs are metabolized by hepatic cytochrome P450 3A4 (CYP3A4), resulting in their reduced bioavailability. In this study, we present the design and evaluation of bio-compatible nanocarriers trapping a natural CYP3A4-inhibiting compound. Our aim in using nanocarriers was to target the natural CY...

Descripción completa

Detalles Bibliográficos
Autores principales: Paolini, Marion, Poul, Laurence, Berjaud, Céline, Germain, Matthieu, Darmon, Audrey, Bergère, Maxime, Pottier, Agnès, Levy, Laurent, Vibert, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546780/
https://www.ncbi.nlm.nih.gov/pubmed/28814868
http://dx.doi.org/10.2147/IJN.S141145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546780/
https://www.ncbi.nlm.nih.gov/pubmed/28814868
http://dx.doi.org/10.2147/IJN.S141145

Ejemplares similares